271 related articles for article (PubMed ID: 22340592)
1. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.
Karnezis T; Shayan R; Caesar C; Roufail S; Harris NC; Ardipradja K; Zhang YF; Williams SP; Farnsworth RH; Chai MG; Rupasinghe TW; Tull DL; Baldwin ME; Sloan EK; Fox SB; Achen MG; Stacker SA
Cancer Cell; 2012 Feb; 21(2):181-95. PubMed ID: 22340592
[TBL] [Abstract][Full Text] [Related]
2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
3. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.
Karnezis T; Shayan R; Fox S; Achen MG; Stacker SA
Oncotarget; 2012 Aug; 3(8):893-906. PubMed ID: 23097685
[TBL] [Abstract][Full Text] [Related]
4. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
5. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
7. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
[TBL] [Abstract][Full Text] [Related]
8. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
12. [Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer].
Chen YN; Gu Y
Ai Zheng; 2009 Dec; 28(12):1337-43. PubMed ID: 19958632
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor D is dispensable for development of the lymphatic system.
Baldwin ME; Halford MM; Roufail S; Williams RA; Hibbs ML; Grail D; Kubo H; Stacker SA; Achen MG
Mol Cell Biol; 2005 Mar; 25(6):2441-9. PubMed ID: 15743836
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
15. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z
Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.
He Y; Rajantie I; Pajusola K; Jeltsch M; Holopainen T; Yla-Herttuala S; Harding T; Jooss K; Takahashi T; Alitalo K
Cancer Res; 2005 Jun; 65(11):4739-46. PubMed ID: 15930292
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeting of lymphatics for therapy.
Stacker SA; Hughes RA; Achen MG
Curr Pharm Des; 2004; 10(1):65-74. PubMed ID: 14754406
[TBL] [Abstract][Full Text] [Related]
18. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
19. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
Harris NC; Davydova N; Roufail S; Paquet-Fifield S; Paavonen K; Karnezis T; Zhang YF; Sato T; Rothacker J; Nice EC; Stacker SA; Achen MG
J Biol Chem; 2013 Mar; 288(12):8176-8186. PubMed ID: 23404505
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.
Achen MG; Stacker SA
Growth Factors; 2012 Oct; 30(5):283-96. PubMed ID: 22817635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
